- 5-year study shows 8-fraction ultrahypofractionated radiotherapy is safe and has low relapse rate in patients with unfavorable intermediate-/high-risk prostate cancer.
Why this matters
- Limited data are available on ultrahypofractionated radiotherapy in unfavorable intermediate-risk patients.
- Phase 2 study of 154 patients with prostate cancer treated with ultrahypofractionated radiotherapy (43.8-45.2 Gy in 8 fractions over 3 weeks).
- Funding: Castilla-Leon Public Health Service.
- 73% of patients received androgen deprivation therapy.
- 92 patients had unfavorable intermediate-/high-risk disease.
- Median follow-up duration was 48 months.
- 5-year biochemical disease-free survival was 94.3% overall and 90% in unfavorable intermediate-/high-risk patients.
- In unfavorable intermediate-/high-risk patients, 5-year cumulative incidence of metastasis was 2.7%.
- 5-year cumulative grade 2-3 genitourinary toxicity was 17.8% and gastrointestinal toxicity was 7.4%.
- 1 patient experienced late grade 3 dysuria; no grade 4-5 toxicity was reported.
- Single group.